drugset / Trial / NCT06932107

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

NCT06932107

Phase 3 Completed 518 enrolled Qilu Pharmaceutical (Hainan) Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The goal of this Interventional study is to evaluate the efficacy and safety of Aprepitant Injection(QLG2174) for preventing PONV in Chinese patients.

Timeline

Start
2024-02-02
Primary completion
2024-05-28
Completion
2024-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 32 mg Intravenous

Indications

No indication recorded.